Retatrutide UK 2026: Eli Lilly Triple G Agonist Weight Loss Injection Awaits MHRA Approval – Up to 28% Loss in Phase 3 Trials vs Mounjaro, Availability Post-May 2026 Unlikely Before 2027 News Retatrutide UK 2026: Eli Lilly Triple G Agonist Weight Loss Injection Awaits MHRA Approval – Up to 28% Loss in Phase 3 Trials vs Mounjaro, Availability Post-May 2026 Unlikely Before 2027 Sumaiya January 9, 2026 0 Retatrutide UK has attracted attention as a new weight‑loss treatment that targets three hormone receptors to reduce... Read More Read more about Retatrutide UK 2026: Eli Lilly Triple G Agonist Weight Loss Injection Awaits MHRA Approval – Up to 28% Loss in Phase 3 Trials vs Mounjaro, Availability Post-May 2026 Unlikely Before 2027